ADVANCED OR METASTATIC SOLID TUMORS

This early-phase study tests an experimental drug called PRTH-101, given alone or with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug helps…

This early-stage study tests a new drug called PMC-309, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see how the body processes the drug. …

This early-phase study tests a new drug called IPH4502 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Nectin-4 found on many cancer cells. The main goals are to check the drug's safety, find the best dos…

This study tests a new drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The drug works by blocking a protein (PARG) that cancer cells need to repair themselves. The main goal…

This early-phase study tests a new drug called LNCB74 in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. LNCB74 is an antibody-drug conjugate designed to deliver a cancer-killing agent dir…

This early-phase study tests a new drug called KGX101, given alone or with envafolimab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body handles the drugs. About 57 pa…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This early-phase study tests a new treatment using immune cells from healthy donors, engineered to recognize and attack cancer cells. About 60 adults with advanced solid tumors that have not responded to standard treatments will receive these cells. The approach uses a tumor biop…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to fight cancer more effective…

This early-phase study tests a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The trial has three parts: first, finding the safest dose; then testing different dosing schedules in esophageal and head & neck cancers. Abo…

This early-phase study tests a new drug called BH3120, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. About 245 adults…

This early-phase study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…

This early-phase study tests a new drug called DAY301 in people with advanced solid tumors (cancers that have spread). The drug is designed to seek out and attack cancer cells while sparing healthy ones. The main goals are to check safety, find the best dose, and see if it shrink…

This is the first study in people testing a new cancer drug called HM16390. Researchers want to find the safest and most effective dose, both by itself and combined with an existing immunotherapy drug (pembrolizumab). The trial will enroll 292 adults with advanced or metastatic s…